AbbVie (ABBV)
(Delayed Data from NYSE)
$193.47 USD
-0.15 (-0.08%)
Updated Sep 20, 2024 04:02 PM ET
After-Market: $193.31 -0.16 (-0.08%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Cash flow Statements
Fiscal Year End for AbbVie Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 4,873.00 | 11,845.00 | 11,549.00 | 4,622.00 | 7,882.00 |
Depreciation/Amortization & Depletion | 8,698.00 | 8,467.00 | 8,521.00 | 6,471.00 | 2,017.00 |
Net Change from Assets/Liabilities | 2,588.00 | -408.00 | -1,322.00 | 938.00 | -1,286.00 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 6,680.00 | 5,039.00 | 4,029.00 | 5,557.00 | 4,711.00 |
Net Cash From Operating Activities | 22,839.00 | 24,943.00 | 22,777.00 | 17,588.00 | 13,324.00 |
Property & Equipment | -777.00 | -695.00 | -787.00 | -798.00 | -552.00 |
Acquisition/ Disposition of Subsidiaries | -1,223.00 | -794.00 | -1,902.00 | -39,610.00 | -1,135.00 |
Investments | -22.00 | 92.00 | -21.00 | 1,464.00 | 2,116.00 |
Other Investing Activities | 13.00 | 774.00 | 366.00 | 1,387.00 | 167.00 |
Net Cash from Investing Activities | -2,009.00 | -623.00 | -2,344.00 | -37,557.00 | 596.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -1,792.00 | -1,225.00 | -690.00 | -769.00 | -621.00 |
Issuance (Repayment) of Debt | -4,149.00 | -12,433.00 | -8,414.00 | -2,683.00 | 29,946.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | -3,699.00 |
Payment of Dividends & Other Distributions | -10,539.00 | -10,043.00 | -9,261.00 | -7,716.00 | -6,366.00 |
Other Financing Activities | -742.00 | -1,102.00 | -674.00 | -333.00 | -552.00 |
Net Cash from Financing Activities | -17,222.00 | -24,803.00 | -19,039.00 | -11,501.00 | 18,708.00 |
Effect of Exchange Rate Changes | 5.00 | -62.00 | -97.00 | -5.00 | 7.00 |
Net Change In Cash & Equivalents | 3,613.00 | -545.00 | 1,297.00 | -31,475.00 | 32,635.00 |
Cash at Beginning of Period | 9,201.00 | 9,746.00 | 8,449.00 | 39,924.00 | 7,289.00 |
Cash at End of Period | 12,814.00 | 9,201.00 | 9,746.00 | 8,449.00 | 39,924.00 |
Diluted Net EPS | 2.72 | 6.63 | 6.45 | 2.72 | 5.28 |
Fiscal Year End for AbbVie Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 2,745.00 | 1,372.00 | 4,873.00 | 4,049.00 | 2,268.00 |
Depreciation/Amortization & Depletion | 4,205.00 | 2,074.00 | 8,698.00 | 6,622.00 | 4,387.00 |
Net Change from Assets/Liabilities | -3,188.00 | 202.00 | 2,588.00 | 2,151.00 | -446.00 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2,549.00 | 392.00 | 6,680.00 | 5,264.00 | 4,303.00 |
Net Cash From Operating Activities | 6,311.00 | 4,040.00 | 22,839.00 | 18,086.00 | 10,512.00 |
Property & Equipment | -434.00 | -193.00 | -777.00 | -572.00 | -353.00 |
Acquisition/ Disposition of Subsidiaries | -10,232.00 | -9,389.00 | -1,223.00 | -670.00 | -513.00 |
Investments | -13.00 | 0.00 | -22.00 | -2.00 | 1.00 |
Other Investing Activities | -11.00 | -6.00 | 13.00 | 35.00 | 25.00 |
Net Cash from Investing Activities | -10,690.00 | -9,588.00 | -2,009.00 | -1,209.00 | -840.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -1,196.00 | -1,197.00 | -1,792.00 | -1,820.00 | -1,852.00 |
Issuance (Repayment) of Debt | 11,515.00 | 14,860.00 | -4,149.00 | -2,355.00 | -2,353.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 3.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | -5,522.00 | -2,772.00 | -10,539.00 | -7,913.00 | -5,286.00 |
Other Financing Activities | -75.00 | -75.00 | -742.00 | -685.00 | -621.00 |
Net Cash from Financing Activities | 4,722.00 | 10,819.00 | -17,222.00 | -12,773.00 | -10,112.00 |
Effect of Exchange Rate Changes | -27.00 | -18.00 | 5.00 | -18.00 | -2.00 |
Net Change In Cash & Equivalents | 316.00 | 5,253.00 | 3,613.00 | 4,086.00 | -442.00 |
Cash at Beginning of Period | 12,814.00 | 12,814.00 | 9,201.00 | 9,201.00 | 9,201.00 |
Cash at End of Period | 13,130.00 | 18,067.00 | 12,814.00 | 13,287.00 | 8,759.00 |
Diluted Net EPS | 0.77 | 0.77 | 0.45 | 1.00 | 1.14 |